California is currently home to 5594 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Recruiting
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Norcal Endocrinology & Internal Medicine, San Ramon, California
Conditions: Obesity, Overweight, Type 2 Diabetes
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Recruiting
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Chao Family Comprehensive Cancer Center, Orange, California
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
Recruiting
This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Modena Allergy & Asthma Clinical Research - La Jolla, La Jolla, California
Conditions: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Recruiting
This is a Phase 2, single-arm, open-label study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: 014, San Francisco, California
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Recruiting
This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread. People can take part in this study if their previous treatment was not successful, or no other treatment exists. The study aims to find the highest dose for the study medicine called BI 765049 that people with advanced cancer can tolerate. Another purpose is to find the most suitable dose and best way of administration of BI 765049 for furt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Valkyrie Clinical Trials, Los Angeles, California
Conditions: Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Recruiting
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-00... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Exalt Clinical Research Inc, Chula Vista, California
Conditions: Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
A Study of Navenibart in Participants With Hereditary Angioedema
Recruiting
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/23/2025
Locations: Site 14, San Diego, California
Conditions: Hereditary Angioedema (HAE)
Patient Reported Experiences With Sparing External Oblique Fascia Vs Standard Inguinal Orchiectomy
Recruiting
The purpose of this study is to evaluate the difference in patient-reported postoperative outcomes between two standard-of-care surgical techniques for radical orchiectomy (inguinal orchiectomy versus external oblique fascia sparing orchiectomy) for treatment of patients with suspected testicular malignancy. The main questions it aims to answer are: 1. Does sparing the external oblique fascia during orchiectomy reduce pain after surgery? 2. Is there a difference in narcotic consumption after su... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Loma Linda University, Loma Linda, California
Conditions: Testicular Cancer
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Recruiting
The purpose of this study is to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Hoag Memorial Presbyterian, Newport Beach, California
Conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD
Recruiting
PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative software improves: certainty for diagnosis of CAD, control of CAD risk factors and efficiency of ICA referral with appropriate PCI compared to the usual care strategy based on current AHA/ACC guidelines for care of symptom... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Valiance Clinical Research- Huntington Park, Huntington Park, California
Conditions: Coronary Artery Disease
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
Recruiting
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13? * Does buntanetap/Posiphen improve function as measured by ADCS-iADL? * What medical issues do participants have, if any, when taking buntanetap/Posiphen? Researchers will compare buntanetap/Pos... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
06/23/2025
Locations: Hope Clinical Research, Canoga Park, California
Conditions: Early Alzheimers Disease
Supportive Training After Cardiac Rehabilitation Including Virtual Engagement
Recruiting
The proposed research seeks to determine whether virtual coaching and social support focusing on key social cognitive factors will be an effective strategy for maintaining physical activity (PA) after completing cardiac rehabilitation (CR). Despite the well-documented benefits of CR, only 15-50% of individuals continue to exercise 6 months after completing CR.4-6 Thus, after 36 sessions (typically 12 weeks), many patients are left without the support necessary to sustain physical activity (PA) a... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
06/23/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Physical Activity Maintenance, Lifestyle (Sedentary Behavior and Physical Activity), Behavioral Intervention